Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

  title={Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy},
  author={Samer Ezziddin and Martin Opitz and Mared Attassi and Kim Biermann and Amir Hossein Nodehi Sabet and Stefan Guhlke and Holger A Brockmann and Winfried W Willinek and Eva Wardelmann and Hans-J{\"u}rgen Biersack and Hojjat Ahmadzadehfar},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
The role of the Ki-67 tumour proliferation index (PI) in predicting the efficacy of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic tumours (GEP-NET) remains undetermined. This single-centre analysis focused on the potential therapeutic impact of this immunohistochemical parameter. A total of 81 consecutive GEP-NET patients treated with 177Lu-DOTA-octreotate (mean activity of 7.9 GBq per cycle, usually four treatment cycles at standard intervals of 3 months) were… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 31 extracted citations


Publications referenced by this paper.
Showing 1-10 of 19 references

PET-CT for neuroendocrine tumors and nuclear medicine therapy options (in German)

  • K Scheidhauer, M Miederer, FC. Gaertner
  • Radiologe
  • 2009
3 Excerpts

Consensus protocol of the German Society of Nuclear Medicine and the section NET of the German Society of Endocrinology; workshop peptide receptor radionuclide therapy

  • KnappWH, R Arnold
  • Updated 2 December
  • 2008
2 Excerpts

Functional imaging of neuroendocrine tumors with combined PET / CT using 68 Ga - DOTATATE ( DOTA - DPhe 1 , Tyr 3 - octreotate ) and 18 F - FDG

  • I Kayani, JB Bomanji, A Groves
  • 2008

Similar Papers

Loading similar papers…